Periprocedural and Short-Term Outcomes of Transfemoral Transcatheter Aortic Valve Implantation With the Sapien XT as Compared With the Edwards Sapien Valve

Mussardo, Marco; Latib, Azeem; Chieffo, Alaide; Godino, Cosmo; Ielasi, Alfonso; Cioni, Micaela; Takagi, Kensuke; Davidavičius, Giedrius; Montorfano, Matteo; Maisano, Francesco; Carlino, Mauro; Franco, Annalisa; Covello, Remo Daniel; Spagnolo, Pietro; Grimaldi, Antonio; Alfieri, Ottavio; Colombo, Antonio

doi:10.1016/j.jcin.2011.05.004

Cited by 67 publications

(51 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[8][9][10][11][12][13][14][15][16][17]21,24,25 This may reflect differences in our population compared with the entire Pivotal Trial cohort or the general population post approval or perhaps a broader indication. The rate of high-grade AV block (complete heart block or Mobitz II second-degree block) was 22.9%.…”

Section: Discussionmentioning

confidence: 99%

“…Studies have found a PPI rate of 18-34% for the CoreValve' versus 4-12% for the SAPIEN' valve (Edwards Lifesciences, Irvine, CA). [9][10][11][12][13][14][15][16][17] Additionally, the CoreValve' has been associated with a higher incidence of procedural related left bundle branch block (LBBB) than the SAPIEN'. [16][17][18][19][20] It is not yet fully understood what causes these marked differences.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and Predictors of Pacemaker Implant Post Commercial Approval of the CoreValve System for TAVR

Lüke¹,

Huntsinger²,

Carlson³

et al. 2016

JICRM

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Incidence and Predictors of Pacemaker Implant Post Commercial Approval of the CoreValve System for TAVR

Lüke¹,

Huntsinger²,

Carlson³

et al. 2016

JICRM

View full text Add to dashboard Cite

“…5,6,26,30,56,57 To reduce the risk of vascular complications, alternative access routes have been proposed (ie, the transapical approach, the transaortic, the subclavian, the transaxillary, the transcarotid, and the retroperitoneal access) which can be considered in patients with an unfavorable iliofemoral anatomy. [58][59][60][61][62] In addition, effort has been made to miniaturize the delivery systems and develop valves with a low crossing profile.…”

Section: Vascular Complicationsmentioning

confidence: 99%

Evolution of Transcatheter Aortic Valve Replacement

Bourantas

Serruys

2014

Circulation Research

View full text Add to dashboard Cite

“…45 Istraaeivanje kod 120 bolesnika je pokazalo da je postignut kratkoroËni uËinak kao i s prethodnom SAPIEN valvulom, ali je bila povezano s tri puta manjim rizikom od velikih vaskularnih komplikacija. 46 Istraaeivanje PARTNER je bila prva prospektivna randomizirana kontrolirana studija za TAVR u svijetu. Bile su formirane su dvije skupine:…”

Section: Aortic Valve Interventionsunclassified

“…45 A trial on 120 patients showed that it had the same short term performance as the earlier SAPIEN valve but was associated with threefold lower risk of major vascular complications. 46 The PARTNER valve trial was the world's first prospective randomised controlled trial for TAVR. It was designed with two arms:…”

Section: Aortic Valve Interventionsmentioning

confidence: 99%

Almanac 2013: novel non-coronary cardiac interventions

Meier

Franzen²,

Lansky³

2013

Cardiol Croat.

View full text Add to dashboard Cite

SAAEETAK:Aktualne inovacije u intervencijskoj kardiologiji dramatiËno su proπirile terapijske moguÊnosti za srËa-ne bolesnike. Intervencijska kardiologija viπe nije ograniËena na lijeËenje koronarne bolesti srca veÊ je moguÊe lijeËiti bolesti zalistaka, raditi na prevenciji moaedanog udara, lijeËenju arterijske hipertenzije, itd. Jedna od najvaaenijih novih moguÊnosti lijeËenja je perkutano lijeËenje aortne stenoze (transkateterska implantacija aortne valvule), buduÊi da je bolest aortne valvule vrlo Ëest problem u bolesnika starije aeivotne dobi, a mnogi od njih imaju visok rizik od operacije. Isto tako, mitralna regurgitacija je Ëesto povezana s pojavom komorbiditeta koji Ëine operaciju visokoriziËnom. MitraClip je obeÊavajuÊe perkutano alternativno rjeπenje za kirurπki popravak ili zamjenu srËanog zaliska. Ostali postupci koji se spominju u ovom preglednom Ëlanku su perkutano zatvaranje aurikule lijevog atrija kao nefarmakoloπka terapija za prevenciju moaedanog udara, renalna denervacija za rezistentnu arterijsku hipertenziju. U ovom se Ëlanku pojaπnjavaju osnovni principi ovih postupaka, najvaaenije kliniËke studije uz dodatne kliniËke podatke o svakom od njih. KLJU»NE RIJE»I: intervencijska kardiologija, intervencijski zahvati na zaliscima. SUMMARY:Recent innovations in interventional cardiology have dramatically expanded the therapeutic options for patients with cardiac conditions. Interventional cardiology is no longer limited to the treatment of coronary artery disease but allows also treatment of valvular disease, stroke prevention, hypertension, etc. One of the most important new treatment options is the percutaneous treatment for aortic valve stenosis (transcatheter aortic valve implantation), since aortic valve disease is a rather common problem in elderly patients, with many of them at high risk for surgery. Similarly, mitral regurgitation is often associated with comorbidities which make surgery high risk. The MitraClip is a promising percutaneous alternative to surgical valve repair or replacement. Other procedures discussed in this review are the percutaneous left atrial appendage closure as a non-pharmacologic therapy to prevent strokes, and renal denervation for resistant hypertension. This review explains the basic principles of these procedures, the most important clinical evidence, and also provides additional recent clinical data on each of these them.

show abstract

Periprocedural and Short-Term Outcomes of Transfemoral Transcatheter Aortic Valve Implantation With the Sapien XT as Compared With the Edwards Sapien Valve

Abstract: The new SXT valve has the same short-term performance as the ESV but seems to be associated with a lower risk of major vascular complications and thus has a broader clinical application.

Cited by 67 publications

References 18 publications

Incidence and Predictors of Pacemaker Implant Post Commercial Approval of the CoreValve System for TAVR

Incidence and Predictors of Pacemaker Implant Post Commercial Approval of the CoreValve System for TAVR

Evolution of Transcatheter Aortic Valve Replacement

Almanac 2013: novel non-coronary cardiac interventions

Contact Info

Product

Resources

About